The landscape of T cell antigens for cancer immunotherapy

A Peri, N Salomon, Y Wolf, S Kreiter, M Diken… - Nature cancer, 2023 - nature.com
The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

Human papillomavirus vaccines: an updated review

L Cheng, Y Wang, J Du - Vaccines, 2020 - mdpi.com
Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past
decade, have shown promising results in decreasing HPV infection and related diseases …

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

EEW Cohen, RB Bell, CB Bifulco, B Burtness… - … for immunotherapy of …, 2019 - Springer
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy

A Pal, R Kundu - Frontiers in microbiology, 2020 - frontiersin.org
Human papillomavirus (HPV)-induced cervical cancer is a major health issue among
women from the poorly/under-developed sectors of the world. It accounts for a high-mortality …

[HTML][HTML] Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies

R Bhattacharjee, SS Das, SS Biswal, A Nath… - Critical reviews in …, 2022 - Elsevier
Purpose Cervical cancer (CC), one of the major causes of death of women throughout the
world is primarily caused due to Human Papilloma Virus (HPV) 16 and 18. The early region …

Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing

AC Chrysostomou, DC Stylianou, A Constantinidou… - Viruses, 2018 - mdpi.com
Cervical cancer is the fourth most frequently occurring cancer in women around the world
and can affect them during their reproductive years. Since the development of the …

Prophylactic and therapeutic HPV vaccines: current scenario and perspectives

Y Mo, J Ma, H Zhang, J Shen, J Chen… - Frontiers in cellular …, 2022 - frontiersin.org
Persistent human papillomavirus (HPV) infection is recognized as the main cause of cervical
cancer and other malignant cancers. Although early detection and treatment can be …

Mucosal and cutaneous human papillomavirus infections and cancer biology

T Gheit - Frontiers in Oncology, 2019 - frontiersin.org
Papillomaviridae is a family of small non-enveloped icosahedral viruses with double-
stranded circular DNA. More than 200 different human papillomaviruses (HPVs) have been …

[HTML][HTML] Tweak to treat: reprograming bacteria for cancer treatment

BFL Sieow, KS Wun, WP Yong, IY Hwang, MW Chang - Trends in cancer, 2021 - cell.com
Recent advancements in cancer biology, microbiology, and bioengineering have spurred
the development of engineered live biotherapeutics for targeted cancer therapy. In …

The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease

AR Garbuglia, D Lapa, C Sias… - Frontiers in …, 2020 - frontiersin.org
Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …